Technology evaluation: G-3139

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 3, 1999, Pages 404-408

  Banerjee, Debabrata ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; MITOXANTRONE; OBLIMERSEN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; REVIEW; SKIN MANIFESTATION;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER CARE FACILITIES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CYCLOPHOSPHAMIDE; DACARBAZINE; FEMALE; GENE THERAPY; GENES, BCL-2; HUMANS; MALE; MICE; MICE, INBRED BALB C; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASM PROTEINS; NEOPLASMS; PACLITAXEL; PATENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; RNA, NEOPLASM; SAFETY; STRUCTURE-ACTIVITY RELATIONSHIP; TAXOIDS; THIONUCLEOTIDES; TREATMENT OUTCOME; UNITED STATES;

EID: 0032991747     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Raynaud F, Orr R, Goddard P, Dizik M, Beck T, Vaghefi M, Woodle M, Judson I, Cotter F: Preclinical pharmacokinetics of G3139, a phosphorothioate antisense to bcl-2 in mice. Proc Am Assoc Cancer Res (1996) 37:Abs 2802.
2. Arnold LJ: The preclinical and clinical experience of antisense ollgonucleotides that target BCL2 expression. Nucleosides Nucleotides Their Biol Applications, 12th International Roundtable, La Jolla, CA, USA, 15-19 September 1996:63(OP48).
3. th International Roundtable, La Jolla, CA, USA, 15-19 September 1996:164(PPI90).
4. Bishop MR, Iverson PL, Bayever E, Graham Sharp J, Greiner TC, Capple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO and Kessinger A: Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol (1996) 14:1320-1326.
5. Orr RM, Raynaud FI, Goddard PM, Judson IR, Beck T, Bryan B, Cotter FE: A preclinical pharmacokinetic study of G3139, A phosphorothioate antisense oligodeoxynucleotide to BCL-2, in Balbc mice. Nucleosides Nucleotides Their Biol Applications, 12th International Roundtable, La Jolla, CA, USA, 15-19 September 1996:227(PPII43).
6. Genta Inc: Form 10-K (1997) March 18.
7. Genta Inc: Genta announces results published in The Lancet and IND approval for U.S. trial in non-Hodgkin's lymphoma. Press Release (1997) April 18.
8. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U: Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst (1997) 89:1027-1036.
9. Genta Inc: Genta announces initiation of phase I/IIa prostate cancer trial at Memorial Sloan Kettering Cancer Center. Press Release (1997) December 3.
10. Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, Beck T, Bryan B, Cotter FE: Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2; after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther (1997) 281(1):420.
11. Genta Inc: Genta announces issue of patent for lead antisense compound that targets the Bcl-2 Gene, implicated in prostate and other cancers. Press Release (1998) April 1.
12. Genta Inc: Genta announces the issuance of two patents directed to high potency antisense compounds that target the production of disease causing pre-RNA. Press Release (1998) June 17.
13. Genta Inc: Genta to commence phase I/IIa malignant melanoma trial of bcl-2 antisense compound In combination with a chemotherapeutic drug; preclinical studies showed significant tumor reduction in mouse transplant model of human melanoma. Press Release (1998) June 18.
14. Genta Inc: Genta signs letter of intent with National Cancer Institute for collaborative research & development agreement/Collaboration will study G3139 in various cancers. Press Release (1998) June 24.
15. Genta Inc: Genta to commence second phase I/IIa prostate cancer trial of Bcl-2 antisense compound. Press Release (1998) July 14.
16. Cotter FE: BCL-2 antisense therapy: in vitro, in vivo and human trial experiences in haematological malignancies. Int Congr Pharmacol (1998) 13th Munich SH 3.3.
17. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, Van Elsas A, Muller M, Wolff K, Eichler H-G, Pehamberger H: bcl-2 antisense therapy chemosensitizes human melanoma In SCID mice. Nat Med (1998) 4:232-234.
18. Genta Inc: Report at American Association for Cancer Research meeting presents scientific basis for clinical trial now underway at British Columbia Cancer Agency / Bcl-2 antisense shows potent anti-tumor effects in preclinical models of prostate cancer. Press Release (1998) December 7.
19. Genta Inc: Genta to commence phase I/IIa lymphoma trial of Bcl-2 antisense compound administered with Cyclophosphamide. Press Release (1999) January 11.
20. Genta Inc: Royal Marsden Hospital to commence phase II trial of Genta's Bcl-2 antisense compound G3139 in non-Hodgkin's lymphoma. Press Release (1999) January 21.
21. Bennett CF: Antisense oligonucleotide therapeutics. Exp Opin Invest Drugs (1999) 8(3):237-253.
22. Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol (1995) 14:541-546.
23. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC: Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev (1994) 4:71-79.